Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00115128

Enrollment

309

Registered

2005-06-22

Start date

2003-11-30

Completion date

2007-09-30

Last updated

2013-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal PBPC Donors

Keywords

normal PBPC donors

Brief summary

The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.

Interventions

DRUGfilgrastim

Normal donors being treated with filgrastim for PBPC mobilization and collection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

- Eligible to be PBPC donor for allogeneic transplantation as determined by local institution

Exclusion criteria

- History of splenectomy - Previous PBPC mobilization attempts - Previous treatment with GCSF or GMCSF

Design outcomes

Primary

Measure	Time frame
Spleen fold change measured by ultrasound	Before, during, and through 1 week post-PBPC mobilization and collection

Secondary

Measure	Time frame
Spleen change associations with filgrastim dose and hematologic variables	Before, during, and through 1 week post-PBPC mobilization and collection

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026